Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Little Green Pharma Ltd (LGP.AX)
AUD0.07
+0.00 (+1.41%)
AU ASX Healthcare Drug Manufacturers - Specialty & Generic
Address
Level 2 6005
West Perth, WA, AU
West Perth, WA, AU
CEO
Paul Frederick Long
Website
littlegreenpharma.com
IPO
2020-02-19
ISIN AU0000074924
Description
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.07
+0.00 (+1.41%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
269.8K
Beta
0.66
Float Shares
284.63M
Free Float %
93.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.11% | -11.00% | -5.32% | -15.24% | -31.54% | -28.80% | -11.00% | -49.14% | -87.19% | -74.57% | -74.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.07
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-01 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
2.05
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+15.2% ★ Q1'26: +85.3% (vs Q3'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-141.8% Q1'26: +77.1% (vs Q3'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-12.4% Q1'26: -2.6% (vs Q3'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-4.6% Q1'26: -2.5% (vs Q3'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-2.3% Q1'26: -2.1% (vs Q3'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.9% Q1'26: +2.3% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.54× Q1'26: 0.91× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
14.04M
est: 2.20M (+538.2%)
|
19.57M
est: 19.90M (-1.7%)
|
25.60M
est.
|
36.82M
est: 36.60M (+0.6%)
|
42.40M
42.40M – 42.40M
+15.8% YoY
|
45.60M
45.60M – 45.60M
+7.5% YoY
|
48.20M
48.20M – 48.20M
+5.7% YoY
|
| EBITDA |
-27.03M
est: -552.6K (-4,791.9%)
|
-4.64M
est: -5.00M (+7.1%)
|
-6.43M
est.
|
-684.0K
est: -1.55M (+56.0%)
|
-1.80M
-1.80M – -1.80M
-15.8% YoY
|
-1.94M
-1.94M – -1.94M
-7.5% YoY
|
-2.05M
-2.05M – -2.05M
-5.7% YoY
|
| EBIT |
—
est: -664.2K (+100.0%)
|
-7.63M
est: -6.01M (-27.0%)
|
-7.73M
est.
|
-4.41M
est: -4.07M (-8.4%)
|
-4.71M
-4.71M – -4.71M
-15.8% YoY
|
-5.07M
-5.07M – -5.07M
-7.5% YoY
|
-5.36M
-5.36M – -5.36M
-5.7% YoY
|
| Net Income |
-24.07M
est: -20.85M (-15.4%)
|
-9.21M
est: -14.81M (+37.8%)
|
-604.5K
est.
|
3.32M
est: -2.75M (+221.1%)
|
-305.0K
-305.0K – -305.0K
+88.9% YoY
|
915.1K
915.1K – 915.1K
+400.0% YoY
|
1.83M
1.83M – 1.83M
+100.0% YoY
|
| SGA |
25.66M
est: 2.36M (+985.6%)
|
8.17M
est: 21.38M (-61.8%)
|
27.51M
est.
|
24.45M
est: 28.96M (-15.6%)
|
33.55M
33.55M – 33.55M
+15.8% YoY
|
36.08M
36.08M – 36.08M
+7.5% YoY
|
38.14M
38.14M – 38.14M
+5.7% YoY
|
| EPS |
-0.10
est: -0.07 (-44.9%)
|
-0.04
est: -0.05 (+24.9%)
|
0.00
est.
|
0.01
est: -0.01 (+222.2%)
|
0.00
0.00 – 0.00
+88.9% YoY
|
0.00
0.00 – 0.00
+400.0% YoY
|
0.01
0.01 – 0.01
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-25 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-20 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 1/5 | 4/5 | 5/5 | 3/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
95.32M
OE per share TTM
0.32
Owner's Yield
346.27%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
253.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-20.8K
Shares Outstanding
305.86M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul Frederick Long | MD & Director | 509.8K | male |
| Angus McDougall Caithness | Chief Financial Officer & Executive Director | 462.3K | male |
| Fleta Jennifer Solomon | Executive Director | 226.6K | female |
| Alistair Warren | Company Secretary | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LGP.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
